ArticleAnti-cancer agents in medicinal chemistry2026
Pomegranate Oil Nanoemulsion as a Nanotherapeutic Strategy Against Breast and Colon Cancer: Induction of Apoptosis and Inhibition of Cell Migration.
Article in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer is increasingly recognized as a chronic condition. However, current anticancer therapies have several limitations that considerably impact patient quality of life. Therefore, we aimed to develop and characterize a pomegranate (Punica granatum) oil-based nanoemulsion (PG-NE) with enhanced anticancer properties. We further aimed to evaluate its cytotoxic, pro-apoptotic, and anti-migratory effects on human breast (MCF-7) and colon (HCT-116) cancer cell lines.
methodsPG-NE was formulated via high-energy emulsification and characterized by dynamic light scattering to determine droplet size, polydispersity index (PDI), and zeta potential. Its cytotoxicity was measured by the MTT assay, whereas apoptosis and migration were assessed by Annexin V/PI flow cytometry and scratchwound- healing assays, respectively.
resultsPG-NE exhibited a mean droplet size, PDI, and zeta potential of 283.67 ± 1.15 nm, 0.17 ± 0.01, and - 35.17 ± 0.06 mV, respectively, indicating uniform nanoscale distribution and good colloidal stability. Compared with mitomycin C (MMC), PG-NE significantly decreased cancer cell viability, enhanced apoptotic induction, and strongly inhibited migration in both MCF-7 and HCT-116 cells. DISCUSSION: The findings indicate that nanoencapsulation enhances the anticancer efficacy of pomegranate oil by increasing its solubility and bioavailability, thereby supporting its potential as a plant-derived nanotherapeutic in integrative oncology.
conclusionPG-NE exhibited potent cytotoxic, pro-apoptotic, and antimigratory activities in vitro. Its physicochemical stability and biological activity support its potential use as a chemopreventive or adjunctive agent.
Indexed as
Identifiers
41944113What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.